STOCK TITAN

Miravo Healthcare™ Announces Second Quarter 2022 Results Release Date and Conference Call Details

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Nuvo Pharmaceuticals Inc. (MRVFF) d/b/a Miravo Healthcare will release its Q2 2022 financial results before the market opens on August 15, 2022. Following the release, a conference call is scheduled for 11:00 a.m. ET on the same day, hosted by President & CEO Jesse Ledger along with senior management. Investors can participate via dial-in or access the audio webcast online. The company focuses on acquiring growth-oriented healthcare products in various therapeutic areas including pain and neurology.

Positive
  • Scheduled Q2 2022 financial results release indicates transparency.
  • Conference call provides an opportunity for investor engagement.
Negative
  • None.

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2022 financial results before markets open on Monday, August 15, 2022.

The Company will subsequently hold a conference call the same day, Monday, August 15, 2022 at 11:00 a.m. ET, hosted by Jesse Ledger, Miravo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

DATE: Monday, August 15, 2022

TIME: 11:00 a.m. ET

DIAL-IN NUMBERS: 416 764 8646 or 1 888 396 8049

The audio webcast and webcast replay can be accessed at:

https://app.webinar.net/5vYkXrPwmEa

About Miravo Healthcare

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.

Investor Relations

905 673-6980 / option 2

ir@miravohealth.com

Source: Nuvo Pharmaceuticals Inc.

FAQ

When will Miravo Healthcare release its Q2 2022 financial results?

Miravo Healthcare will release its Q2 2022 financial results on August 15, 2022.

What time is the conference call for Miravo Healthcare's Q2 results?

The conference call will take place at 11:00 a.m. ET on August 15, 2022.

How can I access the Q2 financial results conference call for MRVFF?

You can access the conference call by dialing 416 764 8646 or 1 888 396 8049.

What are the main therapeutic areas that Miravo Healthcare targets?

Miravo Healthcare targets therapeutic areas including pain, allergy, neurology, and dermatology.

MRVFF

OTC:MRVFF

MRVFF Rankings

MRVFF Latest News

MRVFF Stock Data

11.23M
8.93M
6.32%
17.71%
Drug Manufacturers—Specialty & Generic
Healthcare
Link
Canada
Mississauga